Board of Directors
  • Robyn C. Davis Director

    Ms. Davis has been a director of the Company since June 2013. Since 2000, she has served as Managing Director of AngelHealthcare Investors, LLC, an investment group focused on medical devices, life sciences and specialty pharmaceutical companies.  Ms. Davis also serves as a corporate director of Psychemedics (PMD) and a director at Akston Biosciences, LLC.   For over two decades, Ms. Davis has served as an independent advisor on value-creation, growth strategy, cost reduction, and leadership development to corporations and non-profit organizations.   Earlier in her career, she was a director of the merchant banking services practices for Barents Group, LLC, and a strategy consultant at Bain & Company.  Ms. Davis holds a B.A. from Tufts University, in International Relations, an M.B.A. from Harvard University and received her Executive Master Professional Director Certification from the American College of Corporate Directors.

  • Joseph R. Martin Chairman of the Board

    Mr. Martin has been the chairman of the Azenta Life Sciences board since May 2006. Previously he has served as Co-Chairman of Fairchild Semiconductor Corporation, and previously it’s Sr. Executive Vice President, and Chief Financial Officer.  He also served as the vice chairman of Fairchild’s board of directors. Additionally, Mr. Martin currently serves on the board of directors of BionikLaboratories Corp., a publicly traded medical device and robotics company, and Allegro MicroSystems Inc, a publicly traded manufacturer of high-performance power and semiconductors. Mr. Martin previously served on the boards of SynQor, Incorporated, a manufacturer of power converters, Soitec, Inc., a publicly traded French semiconductor wafer processing company, ChipPac Inc, a publicly traded semiconductor manufacturing company, and Collectors Universe Inc., a publicly traded authentication and grading company of high value collectibles. Mr. Martin is a Trustee at Embry-Riddle Aeronautical University. Mr. Martin holds an Executive Masters Certificate from the American College of Corporate Directors and is a member of the National Association of Corporate Directors.

  • Erica J. McLaughlin Director

    Ms. McLaughlin has been a director since April 2020. Ms. McLaughlin currently serves as Senior Vice President and CFO of Cabot Corporation. Ms. McLaughlin has been with Cabot Corporation since 2002 in a variety of finance roles of increasing responsibility culminating in her current position as Chief Financial Officer. Prior to Cabot, Ms. McLaughlin worked for KPMG, LLP in their audit services group. She also served on the Board of Directors of the Cabot Boston Credit Union from 2013 through 2016 and currently serves as a member of the New York Advisory Board of FM Global.

  • Dr. Krishna G. Palepu Director

    Professor Krishna G. Palepu has been a director of the Company since November 2005 Professor Palepu is the Ross Graham Walker Professor of Business Administration. In addition, he served as the senior advisor to the president of Harvard University from 2012 to 2019. Among his other responsibilities at Harvard Business School, Professor Palepu teaches in several different corporate governance educational programs. Professor Palepu held other positions at Harvard Business School since January 1983, including Senior Associate Dean for International Development and Senior Associate Dean for Research. Professor Palepu was formerly a member of the board of directors of Dr. Reddy’s Laboratories Ltd., an Indian global pharmaceuticals company, from 2002 until 2009, and PolyMedica Corp, a Massachusetts provider of diabetes testing supplies and products, from June 2006 until it was sold in August 2007. Professor Palepu also served as a trustee of The Winsor School from July 2014 to June 2020. Professor Palepu was also formerly a member of the board of directors of BTM Corporation, a privately-owned management solutions provider focused on converging business with technology, and Satyam Computer Services Limited (‘‘Satyam’’), an Indian company whose shares were publicly traded in India and on the New York Stock Exchange. In December 2008, Professor Palepu resigned from the board of Satyam.

  • Michael Rosenblatt, M.D. Director

    Dr. Rosenblatt has been a director since September 2018.  Dr. Rosenblatt currently serves as a Senior Partner of Flagship Pioneering, a Cambridge, Massachusetts-based firm that originates new biotech companies. Prior to Flagship Pioneering, from 2009 through 2016, he was Executive Vice President and Chief Medical Officer of Merck & Co., Inc., and prior to that he held various academic positions, including as Dean of Tufts University School of Medicine and the Robert Ebert Professor of Molecular Medicine and the George R. Minot Professor at Harvard Medical School.

    Since 2015 Dr. Rosenblatt has been on the board of Rubius Therapeutics, a publicly traded company using advanced cellular approaches that harness properties of red blood cells to generate novel therapies. He has been a director of the following privately owned companies since 2016: Flagship Pioneering’s Cobalt Biomedicine, Cygnal Therapeutics, and Ohana Biosciences, and Ferring’s USA subsidiary. Dr. Rosenblatt is a member of the Harvard Medical School Board of Fellows, and the research advisory committees of Massachusetts General, Brigham and Women’s, and Boston Children’s hospitals.

  • Dr. Stephen Schwartz President & Chief Executive Officer

    Dr. Schwartz joined Azenta Life Sciences in April 2010 as President and continued to serve as such until August 2013. He was re-appointed President in May 2016. In 2010, he became Chief Executive Officer and continues to serve in that role. Dr. Schwartz had previously served, from August 2002 until April 20, 2009, as chief executive officer and a director of Asyst Technologies, Inc., a manufacturer of integrated hardware and software automation systems primarily directed at the semiconductor manufacturing industry. He joined Asyst in January 2001 as senior vice president, Product Groups and Operations and was elected chairman of Asyst in January 2003. Prior to joining Asyst, Dr. Schwartz had served since 1987 in various capacities with Applied Materials, Inc., including acting as general manager for Applied Material’s service business and president of Consilium, Inc., an Applied Materials software subsidiary. Since November 2018, Dr. Schwartz has served on the board of directors of Spire Inc., a publicly traded natural gas company.  Dr. Schwartz received his BSEE, MSEE, and Ph.D. in electrical engineering from Purdue University. He also holds an MBA from the University of Chicago.

  • Alfred Woollacott, III Director

    Mr. Woollacott became a director following the Company’s acquisition of Helix Technology Corporation in October 2005. Mr. Woollacott is a certified public accountant and was a partner with the accounting firm of KPMG LLP from 1979 until his retirement in September 2002. He is currently Treasurer of the William H. Hart Realty Company, Inc., Treasurer Hospice and Palliative Care of Martha’s Vineyard, Vice President and Treasurer the Edgartown Golf Club, and President and Treasurer of Hart Haven Community Association. Mr. Woollacott also served, until 2010, as a director of Greencore U.S. Holdings, a wholly owned subsidiary of Greencore Group PLC, an Irish corporation listed on the Irish Stock Exchange, which is an international manufacturer of convenience foods and ingredients.

  • Dr. Mark S. Wrighton Director

    Dr. Wrighton became a director following the Company’s acquisition of Helix Technology Corporation in October 2005. He served as chancellor of Washington University in St. Louis from July 1995 through May 31, 2019 and is now Professor and Chancellor Emeritus.  In September 2021, Dr. Wrighton was appointed interim President of George Washington University effective January 1, 2022.  Dr. Wrighton also serves as a director of Corning Incorporated, a manufacturer of specialty glass and ceramics. He previously served as a director of:  A.G. Edwards, Inc., a financial services company, until 2007; Akermin, Inc, a private company that ceased operations in 2017; and Cabot Corporation, a chemical manufacturer, until 2021.  In June 2020, Dr. Wrighton was appointed to the MIT Corporation. Prior to joining Washington University in St. Louis in 1995, Dr. Wrighton enjoyed a 23-year tenure at MIT, first as a faculty member in chemistry and then as Provost for the final five years.

  • Ellen M. Zane Director

    Ms. Zane has been a director since May 2012.  Ms. Zane is a nationally renowned health care leader who retired as President & Chief Executive Officer of Tufts Medical Center and Tufts Children’s Hospital (formerly the Floating Hospital for Children) in late 2011. Ms. Zane holds two faculty appointments at Tufts University School of Medicine including: Assistant Professor in the Department of Medicine, Division of Clinical Care Research and Assistant Professor of Public Health & Community Medicine.  Additionally, Ms. Zane holds a faculty appointment as Adjunct Assistant Professor of Health Policy and Management at the Harvard T.H. Chan School of Public Health.  

    From 1994 to 2004, Ms. Zane held the position of Network President for Mass General Brigham (formerly Partners HealthCare System, Inc) in Boston.  Prior to that, Ms. Zane was the Chief Executive Officer at Quincy Hospital in Quincy, Massachusetts.  

    Ms. Zane is currently a director of Boston Scientific Corporation (NYSE: BSX), Haemonetics Corporation where she is Board Chair (NYSE: HAE) and Synchrony Financial (NYSE: SYF).  She is also a director of AgNovos Healthcare, LLC in New York, NY, Savista (formerly nThrive) in Alpharetta, GA, the Fiduciary Trust Company in Boston, and the National Association of Corporate Directors New England Chapter, the Vice Chair of the Board of Trustees at George Washington University and Chair of the Board of GW Medical Faculty Associates Board, Washington, DC.  Ms. Zane is also a Trustee of Hebrew Senior Life in Metro Boston and a member of the Board of Massachusetts Development Finance Agency (Appointed by Governor Charles Baker).

    Ms. Zane is a former director of Parexel International (NASDAQ: PRXL), Press Ganey (NYSE: PGND), Lincare Holdings, Inc. (NASDAQ: LNCR), and Variagenics, Inc. (NASDAQ: VGNX), 

    Ms. Zane has a Bachelor of Arts degree from the George Washington University in Washington, DC (1973) and has a Master of Arts degree from the Catholic University of America in Washington, DC (1975).